PMID- 37086469
OWN - NLM
STAT- MEDLINE
DCOM- 20230613
LR  - 20230613
IS  - 1029-2403 (Electronic)
IS  - 1026-8022 (Linking)
VI  - 64
IP  - 6
DP  - 2023 Jun
TI  - Population-level impact of ibrutinib for chronic lymphocytic leukemia in British 
      Columbia, Canada.
PG  - 1129-1138
LID - 10.1080/10428194.2023.2199340 [doi]
AB  - Ibrutinib has dramatically changed the treatment landscape for chronic 
      lymphocytic leukemia (CLL) since its availability in British Columbia (BC), 
      Canada in 2014. We analyzed patterns of use and real-world survival outcomes in 
      370 patients who received ibrutinib for first-line (1 L, n = 35) and 
      relapsed/refractory (R/R, n = 335) CLL between 2014-2018 in BC. Dose reductions 
      and interruptions were frequent in 32% and 27%, respectively. With a median 
      follow-up of 27.6 months, 35% of patients discontinued ibrutinib, primarily for 
      adverse events (AEs) rather than progressive disease. Over the course of 
      treatment, 87% of patients experienced at least one adverse event. The 2-year 
      overall survival (OS) and event-free survival (EFS) were excellent at 83.9% and 
      76.1%, respectively, with medians not reached. However, patients who discontinued 
      ibrutinib had a median OS of 32.5 months and median EFS of only 3.8 months from 
      time of discontinuation, highlighting the need to minimize toxicity in the 
      real-world.
FAU - Khelifi, Rania S
AU  - Khelifi RS
AUID- ORCID: 0000-0002-5578-1102
AD  - Department of Experimental Medicine, University of British Columbia, Vancouver, 
      Canada.
FAU - Huang, Steven J
AU  - Huang SJ
AD  - Leukemia/Bone Marrow Transplant Program of British Columbia, Division of 
      Hematology, Vancouver General Hospital, BC Cancer, University of British 
      Columbia, Vancouver, Canada.
FAU - Savage, Kerry J
AU  - Savage KJ
AD  - Centre for Lymphoid Cancer, BC Cancer, Division of Medical Oncology, University 
      of British Columbia, Vancouver, Canada.
FAU - Villa, Diego
AU  - Villa D
AUID- ORCID: 0000-0002-4625-3009
AD  - Centre for Lymphoid Cancer, BC Cancer, Division of Medical Oncology, University 
      of British Columbia, Vancouver, Canada.
FAU - Scott, David W
AU  - Scott DW
AD  - Centre for Lymphoid Cancer, BC Cancer, Division of Medical Oncology, University 
      of British Columbia, Vancouver, Canada.
FAU - Ramadan, Khaled
AU  - Ramadan K
AD  - St. Paul's Hospital, Division of Hematology, University of British Columbia, 
      Vancouver, Canada.
FAU - Connors, Joseph M
AU  - Connors JM
AD  - Centre for Lymphoid Cancer, BC Cancer, Division of Medical Oncology, University 
      of British Columbia, Vancouver, Canada.
FAU - Sehn, Laurie H
AU  - Sehn LH
AD  - Centre for Lymphoid Cancer, BC Cancer, Division of Medical Oncology, University 
      of British Columbia, Vancouver, Canada.
FAU - Toze, Cynthia L
AU  - Toze CL
AD  - Leukemia/Bone Marrow Transplant Program of British Columbia, Division of 
      Hematology, Vancouver General Hospital, BC Cancer, University of British 
      Columbia, Vancouver, Canada.
FAU - Gerrie, Alina S
AU  - Gerrie AS
AUID- ORCID: 0000-0003-4727-1425
AD  - Department of Experimental Medicine, University of British Columbia, Vancouver, 
      Canada.
AD  - Leukemia/Bone Marrow Transplant Program of British Columbia, Division of 
      Hematology, Vancouver General Hospital, BC Cancer, University of British 
      Columbia, Vancouver, Canada.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20230422
PL  - United States
TA  - Leuk Lymphoma
JT  - Leukemia & lymphoma
JID - 9007422
RN  - 1X70OSD4VX (ibrutinib)
RN  - 0 (Piperidines)
RN  - JAC85A2161 (Adenine)
SB  - IM
MH  - Humans
MH  - *Leukemia, Lymphocytic, Chronic, B-Cell/diagnosis/drug therapy/epidemiology
MH  - British Columbia/epidemiology
MH  - Piperidines/therapeutic use
MH  - Adenine
OTO - NOTNLM
OT  - BTK inhibitor
OT  - Chronic lymphocytic leukemia
OT  - ibrutinib
OT  - population-based
OT  - real-world
EDAT- 2023/04/22 19:42
MHDA- 2023/06/13 06:42
CRDT- 2023/04/22 16:02
PHST- 2023/06/13 06:42 [medline]
PHST- 2023/04/22 19:42 [pubmed]
PHST- 2023/04/22 16:02 [entrez]
AID - 10.1080/10428194.2023.2199340 [doi]
PST - ppublish
SO  - Leuk Lymphoma. 2023 Jun;64(6):1129-1138. doi: 10.1080/10428194.2023.2199340. Epub 
      2023 Apr 22.